Parkman Healthcare Partners LLC Acquires 30,266 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Parkman Healthcare Partners LLC increased its stake in Alnylam Pharmaceuticals by 78.3% in the first quarter, acquiring an additional 30,266 shares, which now makes up 2.2% of their portfolio.
• Alnylam's stock saw a positive reaction, with analysts upgrading the price targets from $390 to as high as $550, reflecting strong market confidence.
• Alnylam recently reported earnings that beat expectations, with a revenue of $773.69 million for the quarter, surpassing analyst predictions of $633.54 million.

Parkman Healthcare Partners LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 78.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 68,938 shares of the biopharmaceutical company's stock after buying an additional 30,266 shares during the period. Alnylam Pharmaceuticals comprises 2.2% of Parkman Healthcare Partners LLC's holdings, making the stock its 14th largest holding. Parkman Healthcare Partners LLC owned approximately 0.05% of Alnylam Pharmaceuticals worth $18,615,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ALNY. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after buying an additional 323,206 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth about $69,292,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of Alnylam Pharmaceuticals by 203.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company's stock worth $76,195,000 after buying an additional 189,128 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after buying an additional 185,783 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Alnylam Pharmaceuticals by 30,759.4% in the 1st quarter. GAMMA Investing LLC now owns 166,332 shares of the biopharmaceutical company's stock worth $44,913,000 after buying an additional 165,793 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 6.0%

Alnylam Pharmaceuticals stock traded up $27.10 during trading hours on Tuesday, hitting $482.13. The company had a trading volume of 3,217,347 shares, compared to its average volume of 1,054,696. The firm has a market cap of $63.20 billion, a P/E ratio of -195.19 and a beta of 0.32. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $484.21. The company has a 50-day moving average price of $393.25 and a two-hundred day moving average price of $312.72.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm's quarterly revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the transaction, the director directly owned 16,804 shares in the company, valued at $7,561,800. This represents a 40.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the transaction, the executive vice president owned 50,121 shares in the company, valued at approximately $22,718,345.67. The trade was a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,594 shares of company stock worth $25,551,456 over the last quarter. Corporate insiders own 1.20% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ALNY shares. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Friday. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. UBS Group raised their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Finally, Piper Sandler raised their target price on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $417.38.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.